Element Materials Technology (Element) has acquired a pharmaceutical analytical testing company, Avomeen, strengthening the Group’s Life Sciences business unit in North America.
Avomeen will deepen Element’s bench strength and technical breadth across a wide range of scientific disciplines, bolstering its offering in formulation chemistry, product manufacturing, extractables & leachables, and large molecule testing.
The company operates out of a facility in Ann Arbor, Michigan. The company is FDA registered, DEA licensed, and ISO accredited.
Avomeen has also been actively involved in efforts to combat the pandemic, leveraging its capabilities to support companies who develop virus diagnostics and therapies, as well as manufacturers of products such as hand sanitizer.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“This is our third acquisition of 2021 and helps to build Element’s growing position in the life sciences sector, expanding our presence in the American pharmaceutical market. As we move into 2021, almost 20% of Element’s revenues are now within the broader life sciences segment covering pharmaceutical, medical device, food and environmental testing services,” Jo Wetz, Element CEO, said. “Avomeen’s service offerings and recent entry into new end markets complement Element’s current pharmaceutical services and clients, and the team’s deep technical knowledge and additional capacity provide us with a significant step-up in scale across the US. Our acquisition of ALG in 2020 and now Avomeen, is quickly positioning Element as a full-service solutions provider within life sciences.”
“We are thrilled to be joining the Element global family and combining our complementary capabilities to offer an even wider array of services and value to our clients. Element’s focus on scientific excellence and quality, coupled with its partnership with clients and employees, aligns well with Avomeen’s values and what we will collectively continue to do as one company,” Mark Harvill, Avomeen CEO, said.